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Chemical makeover inhibits IL-8
On page 2085, Proost et al. find that altering a single arginine turns an inflammatory chemokine 
docile.
The chemokine IL-8, which activates and recruits neutrophils, is secreted as a mixture of 
isoforms that vary in length due to proteolysis. A cut after the first five amino end residues 
produces active protein, whereas cuts elsewhere inhibit activity. Proteolysis might thus be 
one way to control the amount of active IL-8, but it’s not the only one, as Proost et al. now 
find. The transformation of a single arginine into the nonessential amino acid citrulline also 
shuts it down.
Among the IL-8 isoforms secreted by activated human immune cells, one lacked the 
arginine adjacent to the activating cleavage site. The lack of mutations in this isoform 
suggested that the alteration was post-translational, and the protein had not been trimmed, 
suggesting that the arginine had been replaced rather than cleaved off. The alteration did 
not change the isoform’s mass, hinting that the replacement residue might be citrulline, 
which is similar in mass to arginine. Indeed, the authors found citrulline in arginine’s 
place.
Citrulline-containing IL-8 did not efficiently activate the IL-8 receptor on neutrophils, as it 
resisted the activating proteolysis. It also bound poorly to sugar groups that help tether neutrophils 
to blood vessels. When injected into mice, this isoform thus failed to draw neutrophils to the 
injection site.
This modified isoform accounted for only a small fraction of the total IL-8 produced by 
activated cells in culture. Whether cells produce more of this isoform in vivo is not yet 
known. The authors have also yet to determine whether the isoform’s production increases 
during inflammation. The enzyme that turns arginine into citrulline, peptidylarginine 
deiminase (PAD), is secreted mostly by monocytes, which follow neutrophils into inflamed 
sites. Monocytes might turn up PAD production to limit the entry of more neutrophils and 
prevent excessive inflammation.
PAD also citrullinated a few other chemokines, but whether these modifications are similarly 
inhibitory remains to be seen.
Large tumors too slippery for T cells?
On page 2125, Quezada et al. find that big tumors might evade T cell destruction by shutting 
down adhesion molecules.
Tumor-fighting T cells work better when suppressive regulatory T (T reg) cells are not lurking. 
But treatments that either deplete T reg cells or boost anti-tumor T cell activity aren’t enough to 
destroy tumors, as Quezada et al. now show.
As seen in other tumor models, skin tumors in mice were destroyed when the group 
depleted T reg cells before tumor implantation. But if they depleted T reg cells after tumors 
had already developed, the treatment failed, even if the animals were given T cell–boosting 
drugs. Plenty of potential tumor-killing T cells were available, but they did not seem to 
infiltrate the tumors.
Small tumors, at least, were sensitive to T cells. When T reg cell depletion was combined with 
T cell–boosting drugs, small, newly implanted tumors were destroyed. But well-established 
tumors resisted the effects of this regimen.
Established tumors, the group found, had fewer adhesion molecules on surrounding blood 
vessels. To determine whether these adhesives might help T cells invade bigger tumors, the 
group induced adhesion molecules in mice using irradiation. Zapped mice that were then 
injected with anti-tumor T cells along with activity-enhancing drugs fought off tumors. But 
irradiated mice that were also injected with T reg cells put up a weak fight. How tumors dial 
down adhesion molecules as they grow and whether T reg cells coerce them into doing so 
remain to be seen.
The findings might explain why treatments that deplete T reg cells and enhance killer T cell 
activity haven’t fared well in clinical trials. Perhaps combining them with irradiation might make 
them more effective.
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